eCite Digital Repository
Diabetes Medication Assistance Service Stage 1: impact and sustainability of glycaemic and lipids control in patients with Type 2 diabetes
Citation
Krass, I and Mitchell, B and Song, YJC and Stewart, K and Peterson, G and Hughes, J and Smith, L and White, L and Armour, C, Diabetes Medication Assistance Service Stage 1: impact and sustainability of glycaemic and lipids control in patients with Type 2 diabetes, Diabetic Medicine, 28, (8) pp. 987-993. ISSN 1464-5491 (2011) [Refereed Article]
![]() | PDF Restricted - Request a copy 262Kb |
Copyright Statement
The definitive published version is available online at: http://onlinelibrary.wiley.com/
DOI: doi:10.1111/j.1464-5491.2011.03296.x
Abstract
Aims To investigate (i) optimal intensity (four visits vs. six visits) and duration (6 vs. 12 months) of the Diabetes Medication
Assistance Service in community pharmacy and (ii) sustainability of improvements in patients’ diabetes control associated with
differing intensities of intervention.
Methods A national quota sample of 90 community pharmacies in Australia were randomly assigned into group 1 (6-month
Diabetes Medication Assistance Service) or group 2 (12-month Diabetes Medication Assistance Service) and subsequently
recruited a total of 524 patients. A wide range of clinical (HbA1c, blood pressure, lipids) and quality-of-life outcome measures
were assessed.
Results The 6- and 12-month DiabetesMedication Assistance Service resulted in significant and similar reductions in HbA1c
()0.9 mmol ⁄mol; 95% CI )0.7 to )1.1) –, total cholesterol ()0.3 mmol ⁄ l; 95% CI )0.1 to )0.4) and triglycerides
()0.3 mmol ⁄ l;95% CI)0.1 to)0.5).There was also a significant reduction in the number of patientswho were at risk of having
a cardiovascular event in the next 10 years. For the subset of patients for whom data were available at baseline, completion and
18 months, improvements in HbA1c and total cholesterol were sustained at 18 months and triglycerides showed a further
improvement at 18 months.
Conclusions The Diabetes Medication Assistance Service resulted in significant improvements in diabetes control that were
independent of intensity and duration of the service and showed evidence of being sustained at 18 months. The extent and
sustainability of clinical improvements achieved by the Diabetes Medication Assistance Service, together with the resulting
reduction in cardiovascular risk, should translate into future cost savings to healthcare systems by delaying and reducing
diabetes-related complications.
Item Details
Item Type: | Refereed Article |
---|---|
Keywords: | cardiovascular risk, community pharmacy, HbA1c, self-management support, Type 2 diabetes |
Research Division: | Biomedical and Clinical Sciences |
Research Group: | Pharmacology and pharmaceutical sciences |
Research Field: | Clinical pharmacology and therapeutics |
Objective Division: | Health |
Objective Group: | Clinical health |
Objective Field: | Clinical health not elsewhere classified |
UTAS Author: | Peterson, G (Professor Gregory Peterson) |
ID Code: | 71651 |
Year Published: | 2011 |
Web of Science® Times Cited: | 15 |
Deposited By: | Pharmacy |
Deposited On: | 2011-07-27 |
Last Modified: | 2017-11-02 |
Downloads: | 0 |
Repository Staff Only: item control page